Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.19
AGNPRA's Cash-to-Debt is ranked lower than
78% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. AGNPRA: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
AGNPRA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.61 Max: 43.62
Current: 0.19
0.01
43.62
Equity-to-Asset 0.60
AGNPRA's Equity-to-Asset is ranked lower than
57% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. AGNPRA: 0.60 )
Ranked among companies with meaningful Equity-to-Asset only.
AGNPRA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.63 Max: 0.93
Current: 0.6
0.25
0.93
Debt-to-Equity 0.40
AGNPRA's Debt-to-Equity is ranked lower than
60% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. AGNPRA: 0.40 )
Ranked among companies with meaningful Debt-to-Equity only.
AGNPRA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01  Med: 0.3 Max: 1.8
Current: 0.4
0.01
1.8
Piotroski F-Score: 8
Altman Z-Score: 1.00
Beneish M-Score: -1.86
WACC vs ROIC
5.89%
-1.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -19.74
AGNPRA's Operating Margin % is ranked lower than
79% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. AGNPRA: -19.74 )
Ranked among companies with meaningful Operating Margin % only.
AGNPRA' s Operating Margin % Range Over the Past 10 Years
Min: -54.9  Med: 6.95 Max: 14.13
Current: -19.74
-54.9
14.13
Net Margin % 79.17
AGNPRA's Net Margin % is ranked higher than
99% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. AGNPRA: 79.17 )
Ranked among companies with meaningful Net Margin % only.
AGNPRA' s Net Margin % Range Over the Past 10 Years
Min: -34.87  Med: 5.67 Max: 102.76
Current: 79.17
-34.87
102.76
ROE % 14.82
AGNPRA's ROE % is ranked higher than
74% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. AGNPRA: 14.82 )
Ranked among companies with meaningful ROE % only.
AGNPRA' s ROE % Range Over the Past 10 Years
Min: -11.23  Med: 7.32 Max: 19.24
Current: 14.82
-11.23
19.24
ROA % 9.08
AGNPRA's ROA % is ranked higher than
75% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. AGNPRA: 9.08 )
Ranked among companies with meaningful ROA % only.
AGNPRA' s ROA % Range Over the Past 10 Years
Min: -4.32  Med: 4.03 Max: 11.32
Current: 9.08
-4.32
11.32
ROC (Joel Greenblatt) % -242.03
AGNPRA's ROC (Joel Greenblatt) % is ranked lower than
85% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. AGNPRA: -242.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AGNPRA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -242.03  Med: 20.42 Max: 38.44
Current: -242.03
-242.03
38.44
3-Year Revenue Growth Rate 27.40
AGNPRA's 3-Year Revenue Growth Rate is ranked higher than
91% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AGNPRA: 27.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AGNPRA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.3  Med: 17.5 Max: 40.4
Current: 27.4
-16.3
40.4
3-Year EBITDA Growth Rate 41.70
AGNPRA's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. AGNPRA: 41.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AGNPRA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: 13.1 Max: 67.4
Current: 41.7
-47.7
67.4
3-Year EPS without NRI Growth Rate -1.20
AGNPRA's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. AGNPRA: -1.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AGNPRA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -27.1  Med: 5.4 Max: 94.3
Current: -1.2
-27.1
94.3
GuruFocus has detected 1 Warning Sign with Allergan PLC $AGNPRA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AGNPRA's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AGNPRA Guru Trades in Q3 2016

John Burbank 6,000 sh (unchged)
Pioneer Investments 9,275 sh (unchged)
Howard Marks 6,183 sh (-93.18%)
» More
Q4 2016

AGNPRA Guru Trades in Q4 2016

Pioneer Investments 9,275 sh (unchged)
Howard Marks Sold Out
John Burbank Sold Out
» More
Q1 2017

AGNPRA Guru Trades in Q1 2017

Pioneer Investments 9,275 sh (unchged)
» More
Q2 2017

AGNPRA Guru Trades in Q2 2017

Howard Marks 70,296 sh (New)
Pioneer Investments 9,275 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGNPRA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Allergan PLC

SymbolPriceYieldDescription
AGNPRA730.075.605 1/2 % Cum.Conv.Pref.Shs 2015-1.3.18 Series -A-

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:NYSE:PRGO, NAS:HZNP, NAS:ENDP, NAS:INNL » details
Traded in other countries:A60.Germany, AGN N.Mexico,
Headquarter Location:Ireland
Allergan PLC is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and OTC pharmaceutical products.

Allergan is one of the largest specialty pharmaceutical manufacturers. Allergan specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.

Top Ranked Articles about Allergan PLC

Allergan Receives Refusal to File Letter from FDA for Vraylar® (cariprazine) Supplemental New Drug Application (sNDA) for the Treatment of Negative Symptoms in Schizophrenia
New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial
Allergan Innovation Recognized With Three 2017 Allure Best of Beauty Breakthrough Awards
FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
Allergan Launches New Brilliant Distinctions® Patient Loyalty Program
The Allergan Foundation to Donate $150,000 to Support Hurricane Irma Relief Efforts
Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Wallace Weitz's 7 Largest Sales of the 2nd Quarter Guru exits ILG, reduces several other positions
Managing a portfolio of 72 stocks, Wallace Weitz (Trades, Portfolio) sold the following stocks during the second quarter: Read more...
Allergan and Saint Regis Mohawk Tribe Announce Agreements Regarding RESTASIS® Patents
Allergan to Present New Data on Chronic Migraine at the International Headache Congress in Vancouver

Ratios

vs
industry
vs
history
PE Ratio 7.04
AGNPRA's PE Ratio is ranked higher than
94% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.93 vs. AGNPRA: 7.04 )
Ranked among companies with meaningful PE Ratio only.
AGNPRA' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 21.93 Max: 366.63
Current: 7.04
4.95
366.63
Price-to-Owner-Earnings 4.27
AGNPRA's Price-to-Owner-Earnings is ranked higher than
94% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. AGNPRA: 4.27 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AGNPRA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.54  Med: 18.17 Max: 1421.16
Current: 4.27
3.54
1421.16
PB Ratio 0.98
AGNPRA's PB Ratio is ranked higher than
84% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. AGNPRA: 0.98 )
Ranked among companies with meaningful PB Ratio only.
AGNPRA' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.74 Max: 5.9
Current: 0.98
0.87
5.9
PS Ratio 4.79
AGNPRA's PS Ratio is ranked lower than
71% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. AGNPRA: 4.79 )
Ranked among companies with meaningful PS Ratio only.
AGNPRA' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 1.91 Max: 13.79
Current: 4.79
0.99
13.79
Price-to-Free-Cash-Flow 150.59
AGNPRA's Price-to-Free-Cash-Flow is ranked lower than
93% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. AGNPRA: 150.59 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AGNPRA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.64  Med: 17.96 Max: 321.08
Current: 150.59
6.64
321.08
Price-to-Operating-Cash-Flow 52.18
AGNPRA's Price-to-Operating-Cash-Flow is ranked lower than
92% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. AGNPRA: 52.18 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AGNPRA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.99  Med: 14.06 Max: 96.36
Current: 52.18
5.99
96.36
EV-to-EBIT -20.13
AGNPRA's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. AGNPRA: -20.13 )
Ranked among companies with meaningful EV-to-EBIT only.
AGNPRA' s EV-to-EBIT Range Over the Past 10 Years
Min: -310.4  Med: 9.75 Max: 104.6
Current: -20.13
-310.4
104.6
EV-to-EBITDA 47.80
AGNPRA's EV-to-EBITDA is ranked lower than
83% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. AGNPRA: 47.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
AGNPRA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -224.1  Med: 12.6 Max: 589.4
Current: 47.8
-224.1
589.4
EV-to-Revenue 6.49
AGNPRA's EV-to-Revenue is ranked lower than
73% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. AGNPRA: 6.49 )
Ranked among companies with meaningful EV-to-Revenue only.
AGNPRA' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 2.2 Max: 20.8
Current: 6.49
1.2
20.8
Shiller PE Ratio 57.41
AGNPRA's Shiller PE Ratio is ranked lower than
70% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. AGNPRA: 57.41 )
Ranked among companies with meaningful Shiller PE Ratio only.
AGNPRA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.34  Med: 54.49 Max: 2307.73
Current: 57.41
16.34
2307.73
Current Ratio 1.21
AGNPRA's Current Ratio is ranked lower than
78% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. AGNPRA: 1.21 )
Ranked among companies with meaningful Current Ratio only.
AGNPRA' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 2.95 Max: 9.8
Current: 1.21
0.99
9.8
Quick Ratio 1.10
AGNPRA's Quick Ratio is ranked lower than
67% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. AGNPRA: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
AGNPRA' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 2.09 Max: 8.82
Current: 1.1
0.78
8.82
Days Inventory 149.98
AGNPRA's Days Inventory is ranked lower than
72% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. AGNPRA: 149.98 )
Ranked among companies with meaningful Days Inventory only.
AGNPRA' s Days Inventory Range Over the Past 10 Years
Min: 108.11  Med: 126.6 Max: 369.82
Current: 149.98
108.11
369.82
Days Sales Outstanding 67.73
AGNPRA's Days Sales Outstanding is ranked higher than
61% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. AGNPRA: 67.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGNPRA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.05  Med: 65.51 Max: 197.04
Current: 67.73
39.05
197.04
Days Payable 57.12
AGNPRA's Days Payable is ranked lower than
60% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. AGNPRA: 57.12 )
Ranked among companies with meaningful Days Payable only.
AGNPRA' s Days Payable Range Over the Past 10 Years
Min: 28.64  Med: 69.22 Max: 109.48
Current: 57.12
28.64
109.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.60
AGNPRA's Dividend Yield % is ranked lower than
83% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. AGNPRA: 5.60 )
Ranked among companies with meaningful Dividend Yield % only.
AGNPRA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.28  Med: 0.57 Max: 5.65
Current: 5.6
0.28
5.65
Forward Dividend Yield % 7.46
AGNPRA's Forward Dividend Yield % is ranked lower than
65% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. AGNPRA: 7.46 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.65
AGNPRA's 5-Year Yield-on-Cost % is ranked lower than
85% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. AGNPRA: 5.65 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AGNPRA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.28  Med: 0.57 Max: 1.03
Current: 5.65
0.28
1.03
3-Year Average Share Buyback Ratio -24.30
AGNPRA's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. AGNPRA: -24.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AGNPRA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: -6.7 Max: 2
Current: -24.3
-45.6
2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.90
AGNPRA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. AGNPRA: 0.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AGNPRA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.22 Max: 4.58
Current: 0.9
0.59
4.58
Price-to-Median-PS-Value 2.51
AGNPRA's Price-to-Median-PS-Value is ranked lower than
94% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. AGNPRA: 2.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AGNPRA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.65  Med: 2.04 Max: 6.44
Current: 2.51
0.65
6.44
Earnings Yield (Greenblatt) % -4.97
AGNPRA's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. AGNPRA: -4.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AGNPRA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.5  Med: 1.2 Max: 12.3
Current: -4.97
-10.5
12.3
Forward Rate of Return (Yacktman) % 8.49
AGNPRA's Forward Rate of Return (Yacktman) % is ranked lower than
56% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. AGNPRA: 8.49 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AGNPRA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: 7.1 Max: 16.1
Current: 8.49
-8
16.1

More Statistics

Short Percentage of Float0.00%
52-Week Range $691.00 - 907.69

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}